Modern trends in melatonin investigations as a medicine for treatment and prevention certain diseases


DOI: https://dx.doi.org/10.18565/therapy.2019.2.104-109

Ovcharenko A.M., Sidorov A.V.

Federal State Budgetary Educational Institution of Higher Education «Yaroslavl State medical University» of the Ministry of Healthcare of the Russian Federation
The review describes the results of melatonin hormone investigations, the opportunities for use of melatonin preparations for correction of certain pathological processes.
Keywords: neurodegenerative diseases, desynchronosis, malignancies, melatonin, diabetes
Read entire article

Literature


  1. Claustrata B., Bruna J., Chazotb G. The basic physiology and pathophysiology of melatonin. Sleep Medicine Reviews. 2005; 911–24.

  2. Беспятых А.Ю., Бродский В.Я., Бурлакова О.В. и др. Мелатонин: теория и практика. Под ред. С.И. Рапопорта, В.А. Голиченкова. М., 2009. C. 11–12.

  3. Арушанян Э.Б. Универсальные терапевтические возможности мелатонина. Клиническая медицина. 2013; 2: 4–8.

  4. Claustrata B., Lestonb J. Melatonin: Physiological effects in humans. Neurochirurgie. 2015; 61(2–3): 77–84.

  5. Арушанян Э.Б. Мелатонин как лечебное средство: состояние вопроса сегодня и грядущие перспективы. Экспериментальная и клиническая фармакология. 2014; 6: 39–44.

  6. Родионова О.Н., Трубина Н.В., Реутов Э.Ю. и др. Нейрогуморальный и цитокиновый дисбаланс у больных функциональными заболеваниями желудочно-кишечного тракта. Бюллетень Волгоградского научного центра РАМН. 2008; 4(20): 44–47.

  7. Hussain S.A., Khadim H.M., Khalaf B.H. et al. Effects of melatonin and zinc in glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med. J. 2006; 27(10):1483–88.

  8. Арушанян Э.Б., Ованесов К.Б. Значение мелатонина для деятельности почек. Медицинский вестник Северного Кавказа. 2018; 13(1.1): 120–125.

  9. Ganie S.A., Dar T.A., Bhat A.H. et al. Melatonin: A potential antioxidant therapeutic agent for mitochondrial dysfunctions and related disorders. Rejuvenation Res. 2016; 19(1): 21–40.

  10. Федорова Н.В., Никитина А.В., Губанова Е.Н. Нарушения сна в неврологической практике: роль мелатонина в терапии первичных нарушений сна и бодрствования у пациентов с болезнью Паркинсона. Клиницист. 2013; 1: 70–74.

  11. Vincent B. Protective roles of melatonin against the amyloiddependent development of Alzheimer’s disease: a critical review. Pharmacol. Res. 2018.

  12. Литвиненко И.В., Красаков И.В., Тихомирова О.В. Расстройства сна при неосложненной деменцией болезни Паркинсона: результаты контролируемого сравнительного исследования применения мелатонина и клоназепама. Журн. неврологии и психиатрии им. С.С. Корсакова. 2012; 112(12): 26–30.

  13. Liu Y., He H., Huang F. Melatonin in Pain Modulation: Analgesic or Proalgesic? Pain Studies and Treatment. 2014; 2: 50–55.

  14. Pathan H., Williams J. Basic opioid pharmacology: an update. Br. J. Pain. 2012; 6(1): 11–16.

  15. Onaolapo O.J., Onaolapo A.Y. Melatonin in drug addiction and addiction management: Exploring an evolving multidimensional relationship World. J. Psychiatr. 2018; 8(2): 64–74.

  16. Datta P.C., King M.G. Melatonin: Effects on brain and behavior. Neur. Biobehav. Rev. 1980; 4: 451–58.

  17. Cardinali D.P., Lowenstein P.R., Rosenstein R.E. et al. Functional links between benzodiazepine and GABA receptors and pineal activity. Adv. Biochem. Psychopharmacol.1986; 42: 155–64.

  18. Acuña-Castroviejo D., Del Águila C.M., Fernández B. et al. Characterization of ouabain high-affinity binding to rat cerebral cortex. Modulation by melatonin . Eur. J. Pharmacol. 1992; 226: 59–67.

  19. Rudeen P.K., Philo R.C., Symmes S.K. Antiepileptic effects of melatonin in the pinealectomized Mongolian gerbil. Epilepsia. 1980; 21: 149–54.

  20. Molina-Carballo A., Muñoz-Hoyos A., Sánchez-Forte M. et al. Melatonin increases following convulsive seizures may be related to its anticonvulsant properties at physiological concentrations. Neuropediatrics. 2007; 38(3): 122–25.

  21. Dauchy R.T., Xiang S., Mao L. et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res. 2014; 74(15): 4099–110.

  22. Viswanathan A.N., Hankinson S.E., Schernhammer E.S. Night shift work and the risk of endometrial cancer. Cancer Res. 2007; 67: 10618–22.

  23. Schernhammer E.S., Hankinson S.E. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol. Biomarkers Prev. 2009; 18: 74–79.

  24. Sánchez-Barceló E.J., Cos S., Mediavilla D. et al. Melatonin-estrogen interactions in breast cancer. J. Pineal. Res. 2005; 38(4): 217–22.


About the Autors

Alena M. Ovcharenko, 4th year student of the faculty of general medicine of Federal State budgetary educational institution «Yaroslavl State medical University» of the Ministry of Healthcare of Russia. Address: 150000, Yaroslavl, 5 Revolutsionnaya St.
Alexander V. Sidorov, MD, associate professor of the Department of pharmacology, head of the Department of pharmacognosy and pharmaceutical technology of Federal State budgetary educational institution «Yaroslavl State medical University» of the Ministry of Healthcare of Russia. Address: 150000, Yaroslavl, 5 Revolutsionnaya St. Tel.: +7 (915) 999-73-93. E-mail: alekssidorov@yandex.ru


Similar Articles

Back to Content

Бионика Медиа